DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B. et al.
Comparing neoadjuvant NAB-paclitaxel vs. paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial: A randomized phase 3 clinical trial.
JAMA Oncol 2018;
4: 302-8
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.